Opendata, web and dolomites

LIsTEN SIGNED

β-Lactams as flaviviral NS3 protease inhibitors

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 LIsTEN project word cloud

Explore the words cloud of the LIsTEN project. It provides you a very rough idea of what is the project "LIsTEN" about.

warhead    host    potent    previously    ns3    serine    inhibitor    consist    consequence    cell    enzyme    lactam    unnatural    valuable    catalytic    selectivity    significantly    disease    asia    global    inhibitors    warheads    billion    diseases    stability    climate    emerged    parts    inhibitory    beta    group    bond    coast    protease    moment    moderate    zika    threat    agents    virus    spread    denv    compounds    residue    improvement    sub    site    biochemical    near    coupled    covalent    medical    america    replication    derivatives    amino    regions    flaviviral    affinity    strategy    reduce    moiety    metabolic    exist    infections    natural    lactams    acids    off    purpose    permeability    synthesized    nile    culture    treatment    zikv    possibility    wnv    warming    assays    outbreak    accordingly    membrane    active    west    united    peptide    ameliorate    mediterranean    tropical    potency    people    binding    act    living    electrophilic    incorporation    adriatic    dengue   

Project "LIsTEN" data sheet

The following table provides information about the project.

Coordinator
RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG 

Organization address
address: SEMINARSTRASSE 2
city: HEIDELBERG
postcode: 69117
website: www.uni-heidelberg.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Project website https://www.ipmb.uni-heidelberg.de/chemie/klein/drazic.html
 Total cost 171˙460 €
 EC max contribution 171˙460 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2016
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2017
 Duration (year-month-day) from 2017-05-02   to  2019-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG DE (HEIDELBERG) coordinator 171˙460.00

Map

Leaflet | Map data © OpenStreetMap contributors, CC-BY-SA, Imagery © Mapbox

 Project objective

Flaviviral infections already represent a threat to 2.5 billion people living in tropical and sub-tropical regions. As a consequence of climate change and global warming in the near future these infections are expected to spread to areas with moderate climate and the possibility of disease outbreak will exist in Europe, especially around the Mediterranean and Adriatic coast, as well as in the United States of America and large parts of Asia. At the moment no medical treatment against flaviviral diseases is available. Recently, peptide-based compounds which act as flaviviral NS3 protease inhibitors, emerged as potent agents against dengue virus (DENV), Zika virus (ZIKV) and West Nile virus (WNV). These compounds consist of two to four natural or unnatural amino acids and act by binding to the active site of the protease. Accordingly, the incorporation of an electrophilic warhead, a moiety which would facilitate the covalent binding of the inhibitor to the catalytic serine residue, into the peptide inhibitor represents a valuable strategy for the improvement of potency of such inhibitors. The goal of the proposed project is to investigate the potential of β-lactams as electrophilic warheads in DENV, ZIKV and WNV protease inhibitors. For that purpose, new β-lactam derivatives will be synthesized, coupled to peptide inhibitors previously developed by the host group and their affinity to the target will be evaluated by biochemical assays. The most potent compounds will be characterized in more detail and their activity against dengue virus replication in cell culture, off-target binding, membrane permeability and metabolic stability will be studied. We expect the formation of a covalent bond between inhibitor and active site of the enzyme to significantly improve inhibitory activity by increasing binding affinity, as well as to ameliorate selectivity and reduce off-target binding.

 Publications

year authors and title journal last update
List of publications.
2019 Tonko Dražić, Sara Kopf, James Corridan, Mila M. Leuthold, Branimir Bertoša, Christian D. Klein
Peptide-β-lactam Inhibitors of Dengue and West Nile Virus NS2B-NS3 Protease Display Two Distinct Binding Modes
published pages: 140-156, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.9b00759
Journal of Medicinal Chemistry 63/1 2020-02-12

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LISTEN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LISTEN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

TCFLAND2SEA (2020)

Thawing Carbon From LAND to SEA: Microbial Degradation of Organic Matter and Response to Thawing Permafrost in the Northeast Siberian Land-Shelf System

Read More  

EVOMET (2019)

The rise and fall of metastatic clones under immune attack

Read More  

IRF4 Degradation (2019)

Using a novel protein degradation approach to uncover IRF4-regulated genes in plasma cells

Read More